Matches in Nanopublications for { ?s ?p "DDI between Lidocaine and Tacrine - The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Lidocaine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Lidocaine is initiated, discontinued or if the dose is changed. [drugbank_resource:DB00281_DB00382]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00281_DB00382 label "DDI between Lidocaine and Tacrine - The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Lidocaine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Lidocaine is initiated, discontinued or if the dose is changed. [drugbank_resource:DB00281_DB00382]" assertion.